Table 5:

Grade 3 or 4 treatment-emergent adverse events reported before and after 24 months of study drug in the safety population

	≤24 months of elotuzumab*			>24 months of elotuzumab*
	10 mg/kg (n=36)	20 mg/kg (n=37)	All (N=73)	10 mg/kg (n=17)	20 mg/kg (n=13)	All (N=30)
≥one grade 3 or 4 event	31 (86%)	25 (68%)	56 (77%)	14 (82%)	4 (31%)	18 (60%)
Lymphopenia	9 (25%)	5 (14%)	14 (19%)	1 (6%)	0	1 (3%)
Neutropenia	6 (17%)	7 (19%)	13 (18%)	2 (12%)	0	2 (7%)
Thrombocytopenia	6 (17%)	6 (16%)	12 (16%)	1 (6%)	0	1 (3%)
Anaemia	4 (11%)	5 (14%)	9 (12%)	2 (12%)	0	2 (7%)
Hyperglycaemia	2 (6%)	5 (14%)	7 (10%)	0	0	0
Leucopenia	3 (8%)	4 (11%)	7 (10%)	1 (6%)	0	1 (3%)
Diarrhoea	3 (8%)	2 (5%)	5 (7%)	3 (18%)	0	3 (10%)
Fatigue	3 (8%)	2 (5%)	5 (7%)	1 (6%)	0	1 (3%)
Pneumonia	3 (8%)	2 (5%)	5 (7%)	0	2 (15%)	2 (7%)
Hypokalaemia	3 (8%)	1 (3%)	4 (5%)	1 (6%)	0	1 (3%)
Back pain	2 (6%)	1 (3%)	3 (4%)	1 (6%)	0	1 (3%)
Syncope	2 (7%)	0	2 (3%)	2 (12%)	0	2 (7%)
Dyspnoea	1 (3%)	1 (3%)	2 (3%)	2 (12%)	0	2 (7%)

Data are number (%). Adverse events listed by preferred terms as defined in the Medical Dictionary for Regulatory Activities, version 16.1.

^*Sample sizes used as denominator for percentages.